Sai Parenterals Ltd press release, Q2 FY27
The company's FY27 revenue target is Rs. 750 crore, of which H1 FY27 represents approximately 50%, ahead of the guided 45:55 phasing between the two halves.
By ScoutQuest · · 1 min read
- FY27 revenue target
- Rs. 750 crore
- EBITDA Q2 FY27
- Rs. 41.4 crore (up 67.4% q-o-q)
- EBITDA margin Q2 FY27
- 21.1% in Q2 FY27 from 23.3% in Q2 FY26
- Release
- Results press release
- Period
- Q2 FY27
_Consolidated · Q2 & H1 FY27_
📊 EBITDA, Q2 FY27: Rs. 41.4 crore (up 67.4% q-o-q)
📌 The company says output will ramp up from Q4 FY27, most of the additional volume serving Australia and New Zealand.
🏭 Depreciation and amortisation rose to Rs. 25.1 crore in Q2 FY27 from Rs. 8.1 crore in Q1 FY27 on capitalisation of the Unit III expansion and Noumed assets and the Saicriti consolidation. EBITDA margin slipped to 21.1% in Q2 FY27 from 23.3% in Q2 FY26.
📌 The release notes that Q2 and H1 FY27 consolidated figures include a full quarter of Noumed Pharmaceuticals while the year-ago figures do not, so the year-on-year comparison is not like-for-like.
Also from Sai Parenterals
Sai Parenterals investor presentation: Q2 FY27 revenue jumps on Noumed consolidation as Rs. 571 crore capex builds
1 Nov 2026
Consolidated results for the quarter Ended 30.09.2026
1 Nov 2026
Q2 FY27 results, buyout of remaining 25% in SP Analytics, Saicriti Pharma deal completed
1 Nov 2026
More numbers
- Revenue from operations, Q2 FY27Rs. 196.1 crore
- PAT, Q2 FY27Rs. 10.5 crore
- Revenue from operations, H1 FY27Rs. 376.0 crore
- PAT, H1 FY27Rs. 18.4 crore
- EBITDA, Q2 FY27Rs. 41.4 crore
- EBITDA margin, Q2 FY2721.1%
- Gross margin, Q2 FY2747.5%
- Unit III production capacity155 million units a month
- Injectable capacity after Saicriti completionapproximately 154.66 million units
- Contracted Australian OTC supply (order book)approximately Rs. 1,506 crore
- Investment in 60% stake in Prathyak LaboratoriesRs. 15 crore
- Depreciation and amortisation, Q2 FY27Rs. 25.1 crore
- FY27 revenue targetRs. 750 crore
- Order bookAUD 232 million (approximately Rs. 1,506 crore)
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.